



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents available at [ScienceDirect](https://www.sciencedirect.com)

Diabetes Research
and Clinical Practice

journal homepage: www.elsevier.com/locate/diabres



International
Diabetes
Federation



The impact of COVID-19 on people with diabetes in Brazil



Mark Thomaz Ugliara Barone^{a,b,c,d,*}, Simone Bega Harnik^e, Patrícia Vieira de Luca^{c,f}, Bruna Letícia de Souza Lima^{b,c}, Ronaldo José Pineda Wieselberg^{a,b,c,d}, Belinda Ngongo^g, Hermelinda Cordeiro Pedrosa^{d,h}, Augusto Pimazoni-Netto^{d,i}, Denise Reis Franco^{b,d}, Maria de Fatima Marinho de Souza^{c,j}, Deborah Carvalho Malta^k, Viviana Giampaoli^e

^a International Diabetes Federation (IDF), 166 Chaussee de La Hulpe B-1170, Brussels, Belgium

^b ADJ Diabetes Brasil (ADJ), Rua Padre Antônio Tomás, 213, Zip Code 05003-010, Água Branca, São Paulo, SP, Brazil

^c Fórum Intersetorial para Combate às DCNTs no Brasil (ForumDCNTs), Rua Padre Antônio Tomás, 213, Zip Code 05003-010, Água Branca, São Paulo, SP, Brazil

^d Sociedade Brasileira de Diabetes (SBD), Rua Afonso Braz 579, Salas 72/74, Vila Nova Conceição, Zip Code 04511-011, São Paulo, SP, Brazil

^e Universidade de São Paulo (USP), Instituto de Matemática e Estatística, Departamento de Estatística, Rua do Matão 1010, Cidade Universitária, Zip Code 05508-090, São Paulo, SP, Brazil

^f Associação Brasileira de Hipercolesterolemia Familiar (AHF), Rua Machado Bittencourt 190, Vila Clementino, Zip Code 04044-000, São Paulo, Brazil

^g Pan African Women in Health (PAWH), P.O.Box 95535, Grant Park, Johannesburg, South Africa

^h Research Centre, Endocrinology Unit - Regional Taguatinga Hospital - Secretary of Health, Brasília, Federal District and Brazilian Society of Diabetes (SBD), Rua Afonso Braz 579, Salas 72/74, Vila Nova Conceição, Zip Code 04511-011, São Paulo, SP, Brazil

ⁱ Hospital do Rim e Hipertensão - Centro de Hipertensão e Metabologia Cardiovascular, Grupo de Educação e Controle do Diabetes, Rua Leandro Dupret, 365, Vila Clementino, Zip Code 04025-011, São Paulo, SP, Brazil

^j Vital Strategies, Public Health Programs, Rua São Bento, 470, cj. 104, Centro, Zip Code 01010-010, São Paulo, SP, Brazil

^k Universidade Federal de Minas Gerais (UFMG), Escola de Enfermagem, Departamento de Enfermagem Materno-Infantil e Saúde Pública, Avenida Alfredo Balena 190, Santa Efigênia, Zip Code 30130-100, Belo Horizonte, MG, Brazil

ARTICLE INFO

Article history:

Received 17 May 2020

Received in revised form

18 June 2020

Accepted 29 June 2020

Available online 3 July 2020

Keywords:

COVID-19

Coronavirus

Diabetes

Brazil

ABSTRACT

The present study aims at identifying main barriers faced by people living with diabetes in Brazil during the COVID-19 pandemic.

Methods: In a convenience sampling study, data were collected from 1701 individuals, aged 18 or above; 75.54% female participants; 60.73% T1D and 30.75% T2D, between April 22nd and May 4th, using an anonymous and untraceable survey containing 20 multiple choice questions (socio-demographic; health status and habits of life during COVID-19 pandemic). Relationship between variables was established using the multiple correspondence analysis technique.

Results: 95.1% of respondents reduced their frequency of going outside of their homes; among those who monitored blood glucose at home during the pandemic (91.5%), the majority (59.4%) experienced an increase, a decrease or a higher variability in glucose levels; 38.4% postponed their medical appointments and/or routine examinations; and 59.5% reduced their physical activity. T1D, the youngest group, was more susceptible to pre-

* Corresponding author at: ADJ Diabetes Brasil, Rua Padre Antônio Tomás, 213, Zip Code 05003-010, Água Branca, São Paulo, SP, Brazil.
E-mail address: mark.barone@alumni.usp.br (M.T.U. Barone).

<https://doi.org/10.1016/j.diabres.2020.108304>

0168-8227/© 2020 Elsevier B.V. All rights reserved.

Pandemic
SARS-CoV-2

senting COVID-19 symptoms despite not being testing; whilst the T2D group had higher frequency of comorbidities that are additional risk factors for COVID-19 severity.

Conclusions: This study provides a first hand revelation of the severity of COVID-19 on individuals with diabetes in Brazil. Their habits were altered, which impacted their glycemia, potentially increasing the risk of poor outcomes and mortality if infected by SARS-CoV-2, and of acute and chronic diabetes complications.

© 2020 Elsevier B.V. All rights reserved.

1. Introduction

The COVID-19 outbreak has led to an unprecedented global health crisis, testing health systems' preparedness and ability to cope with a pandemic response [1–4]. Brazil experienced a similar challenge. The first SARS-CoV-2 case was officially reported in December 2019 in Wuhan, China, and rapidly spread in the entire country and beyond within 30 days [5–7]. The first suspected case in Latin America was reported on January 27th in Brazil and the first case was confirmed in the same country on February 26th of 2020 [2,3,7]. A series of measures were put in place to prepare Brazil for the anticipated health crisis prior to the declaration of COVID-19 as a Public Health Emergency of International Concern, on January 30th [2], and then a pandemic, on March 11th [8]. Following these international alerts, less than a month after the first confirmed case, on March 20th, the Brazilian Ministry of Health recognized that community transmission was already happening in Brazil [2].

Infection by SARS-CoV-2 causes major disruptions and threats, in addition to the loss of human lives, with case fatality rate ranging from 0.2% in Germany, to 7.7% in Italy [9], the impact of COVID-19 is beyond imagination and is sparking a global mourning, booming a feeling of unsafety and uncertainty. On July 5th, according to the World Health Organization (WHO), 11,301,850 cases and 531,806 deaths due to COVID-19 were confirmed in 216 countries areas or territories with cases [10]. On this same day, the number of cases and mortality in Brazil had reached 1,603,055 and 64,867 respectively, with a case fatality rate of 4.0% [11]. While this is the highest number of cases and one of the highest case fatality rate in Latin America [12], scientists argue that cases and mortality are extremely underscored due to the low number of tests performed among other reasons [1,4,12,13] by possible 14–20 times the official reported figures [14].

Authors of the first Chinese and Italian reports alerted for the worse prognosis of individuals with diabetes and other noncommunicable disease (NCDs), in comparison with populations of the same age group without chronic health conditions [5,15–18]. Further retrospective studies have revealed that, within this group of individuals, hyperglycemia was associated with higher severity and mortality rates [15,19,20,21], for reasons under investigation [22,23]. Additionally, usual comorbidities such as hypertension, cardiovascular disease, older age, and gender (male) also complement increased severity and mortality risks of individuals with diabetes hospitalized due to COVID-19 [24].

With a prevalence as high as 16.8 million people or 11.4% of the population between 20 and 79 years old, Brazil is

among the top 5 countries regarding diabetes prevalence [25]. Moreover, it observes more than 135,000 deaths caused by this condition and its complications yearly [25]. Brazil struggles with the continuous treatment routine of impacted populations; only 28.8% are considered to be in target, having a glycated hemoglobin A1C below 7.0% (53 mmol/mol) [26]. Consequently, 71.2% of Brazilians with diabetes belong to a subgroup more exposed to hyperglycemia, which makes them vulnerable to even higher risk of poor outcomes when infected by the SARS-CoV-2 virus.

This state of affairs calls for deep commitments from the public health in all its forms and a concrete alignment with the WHO. Unfortunately, in the midst of the fight against this novel virus, Brazil experienced a troublesome atmosphere of political disputes, blinding authorities to make swift decisions aligned with the global technical recommendations [1,4,12]. This also harmed adjustments to continue the proper follow-up and management of other diseases, including both communicable and NCDs. For these reasons, the present study aims to investigate challenges encountered by people living with diabetes in Brazil during the COVID-19 pandemic.

2. Method

Data from individuals with diabetes were collected through an anonymous and untraceable survey containing 20 multiple choice questions in Portuguese. The authors shared this survey on websites and social media including Facebook and WhatsApp, through their affiliated institutions, co-ligated or partner entities, and diabetes social media groups. Hence, the convenience sampling nature of this study. In addition to being a person living with diabetes, individuals needed to be legally adults (above 18 years old) and accept the terms to share anonymous and untraceable answers. Survey responses were collected from April 22nd through May 4th.

The first question provided a complete overview of the questionnaire and required confirmation of the health condition (diabetes) by the respondent. This was followed by socio-demographic questions related to age, gender, state of residence, capital/inland/coast, education level, number of people living in the household, and nature of the health system which could be public, private or both. Subsequent questions served to identify the health status of the participants, asking about diabetes type, and presence and type of comorbidity. All remaining questions covered aspects attributed to the COVID-19 pandemic: frequency of going outside, strategies to protect from infection when outside, noted changes in the glycemic levels, access to medical care, changes in eating

habits and physical activity, changes in smoking and drinking habits, and suspected or confirmed COVID-19 infection by the respondent or cohabitant family member. At the end of the survey, the respondent could leave a comment. Several questions and their answers were regarding subjective perceptions, such as “my blood glucose increased”, “I am eating more” or “I am exercising much less” than before the pandemic. Therefore, answers should not be interpreted as objective measurements, but as subjective comparisons with the pre-pandemic states.

A multivariate analysis of dimensions of COVID-19 and types of diabetes (type 1 diabetes - T1D; type 2 diabetes - T2D; others: LADA, MODY, gestational; and unknown) was performed with multiple correspondence analysis (MCA) in R (version 3.6.1) and RStudio (version 1.1.453) [27].

3. Results

The survey was answered by 1701 individuals, 75.54% were female respondents, 70.78% between 18 and 50 years old, 64.96% of respondents were from Southeast of Brazil, and the main diabetes types were type 1 (60.73%) and type 2 (30.75%) (full socio-demographic profile in table 1). Among the main reported consequences of the COVID-19 pandemic were: 95.1% reduced frequency of going outside home (26.9% never went outside since the beginning of the pandemic); among the ones who monitored their blood glucose

at home (91.5%), the majority (59.4%) experienced a deterioration, which included: 31.2% reported greater variability than before the pandemic, 20% higher glycemia and 8.2% lower glycaemic levels. Moreover, 38.4% postponed medical appointments and/or routine exams, and 40.2% did not schedule a medical appointment since the onset of the pandemic. Among recommended habits, slated for diabetes treatment, physical activity was the most impacted, with a reduction reported by 59.5% of the respondents (14.7% with a slight reduction and 44.8% with a great reduction). See Table 2 for habits and behaviors.

Regarding comorbidities, for the current study and analysis, we opted to group them into the following: 1) “Mental Health” which includes the following conditions: depression, anxiety, bulimia, anorexia and diabulimia; and 2) “Cardiovascular Diseases” comprising: stroke, infarction, hypertension and dyslipidemia. Two other groups were already established in the survey as single answers, which had a parenthesis to facilitate comprehension, the “Diabetes Related Complications” with: retinopathy, neuropathy and diabetic renal disease; and the “Respiratory Diseases”: asthma and COPD (Table 1).

The analysis revealed the association between age and the occurrence of symptoms of COVID-19, type of diabetes and some of the comorbidities evaluated (Fig. 1). People with T1D were among the youngest and appeared in proximity to mental health diseases category, but also close to the no-

Table 1 – Socio-demographics and health status of the study population (n = 1701).

Gender	n	%	Education	n	%
Male	414	24,34%	Elementary, incomplete	52	3,06%
Female	1285	75,54%	Elementary, complete	46	2,70%
Non-Binary	2	0,12%	High school, incomplete	55	3,23%
			High school, complete	355	20,87%
Age (years)	n	%	College degree incomplete	312	18,34%
18–30	395	23,22%	College degree complete	434	25,51%
30–40	453	26,63%	Post-graduation	447	26,28%
40–50	351	20,63%			
50–60	271	15,93%	Health Service Coverage	n	%
60–70	164	9,64%	Public (SUS)	479	28,16%
70–80	59	3,47%	Private (Out of pocket/Health Insurance)	657	38,62%
More than 80	8	0,47%	Both	565	33,22%
Brazil Region	n	%	Comorbidities	n	%
North	34	2,00%	Nothing/Unknown	688	40,45%
Northeast	223	13,11%	CVD*	674	39,62%
Midwest	107	6,29%	Mental Disease**	473	27,81%
Southeast	1105	64,96%	Obesity	273	16,05%
South	232	13,64%	Diabetes related complications	267	15,70%
			Asthma/COPD	82	4,82%
Town Type	n	%	Diabetes Type	n	%
Capital	962	56,55%	Type 1	1033	60,73%
Inland	680	39,98%	Type 2	523	30,75%
Coast	59	3,47%	LADA	67	3,94%
			MODY	14	0,82%
			Gestational	4	0,24%
			Unknown	60	3,53%

* Hypertension, previous stroke, myocardial infarction or dyslipidemia.

** Depression, anxiety, diabulimia, anorexia or bulimia.

Table 2 – COVID-19 impact on selected habits and behaviors (n = 1701).

Blood Glucose (BG) Impact	n	%	Physical Activity	n	%
People monitoring BG	1557	91,53%	High increase	39	2,29%
Deteriorated BG	925	59,41%	Low increase	79	4,64%
Higher BG	312	20,04%	No change	571	33,57%
Lower BG	128	8,22%	Low reduction	250	14,70%
Greater variation	485	31,15%	High reduction	762	44,80%
No changes	632	40,59%			
No BG measuring	144	8,47%	TV Time	n	%
			High increase	499	29,34%
Number of Meals	n	%	Low increase	332	19,52%
High increase	88	5,17%	No change	656	38,57%
Low increase	292	17,17%	Low reduction	141	8,29%
No change	1009	59,32%	High reduction	73	4,29%
Low reduction	256	15,05%			
High reduction	56	3,29%	Internet Time	n	%
			High increase	616	36,21%
Food Intake	n	%	Low increase	294	17,28%
High increase	110	6,47%	No change	632	37,15%
Low increase	397	23,34%	Low reduction	124	7,29%
No change	815	47,91%	High reduction	35	2,06%
Low reduction	319	18,75%			
High reduction	60	3,53%			




Fig. 1 – MCA for prevalence of cardiovascular diseases, obesity, mental disorders, respiratory diseases, type of diabetes, age (the horizontal axis is a progression of ages of the respondents), symptoms of COVID-19, health system, symptoms (supplementary), and glycaemic measurements (supplementary).

cardiovascular conditions, no-obesity and no-respiratory disease categories. They were alarmingly close to the category that, despite having symptoms of COVID-19, had no testing for SARS-CoV-2. Not measuring the blood glucose is close to T2D and unknown diabetes type. T2D, not surprisingly, was more associated than other types with older age, cardiovascular diseases and obesity. It is also worth noting that T2D and

older group were the closest to test positive for SARS-CoV-2. In opposition, individuals who had symptoms of COVID-19 and were not tested (125 people or 7.35%) presented higher proximity to increased blood glucose (Fig. 1).

Measuring blood glucose was related with food consumption and working out, as depicted on Fig. 2. Individuals that experienced decrease in blood glucose levels, increased




Fig. 2 – MCA for glycemya, food consumption, physical activities, and type of diabetes (supplementary).

physical activity and decreased food consumption. Meanwhile, higher food consumption and reduced physical activity were associated with higher blood glucose levels. While it seems that the pandemic had a higher impact on habits

and glycemya levels of T1D individuals (right side of Fig. 2), with significant perceived changes, T2D respondents seem to have maintained most of their habits during this period.



Fig. 3 – MCA for glycemya measures, method for buying/receiving medicine, health system, and type of diabetes (supplementary).

Individuals who exclusively use the Brazilian public health system (Unified Health System - SUS), which serves more than 70% of the Brazilian population [28] (in our case, 28.16% of the respondents), were who kept venturing out during the pandemic and experienced an increase of blood glucose levels, as shown in Fig. 3. T1D individuals were the closest to the use of both health systems (SUS and private) and also experienced higher glycemic variability (ups and downs). They had the ability to have friends or relatives to buy or collect their medicines and medical supplies. Users of the private health system were closer to experience no glycemic changes during the pandemic (the same), and used their own stocks of medicine and medical supplies or ordered for home delivery from private pharmacies (Fig. 3).

4. Discussion

The results above unveil short, mid and long-term risks for individuals with diabetes in Brazil. While the federal government and some states made initial commitments and plans [2], knowing the risks for poor prognosis among individuals living with diabetes and/or other NCDs if infected by SARS-CoV-2, our data revealed that implemented measures did not cover most of this population. The strategy to distribute medicines and medical supplies for 90 days, as recommended by different organizations in order to avoid monthly trips [29,30], were effective for only 21% of the 64.5% who received their medication and supplies from SUS (or 13.5% of the total respondents). This provision of medicines and supplies for 3 months, avoiding the monthly rounds to public primary healthcare facilities or pharmacies, seemed to be one of the only specific policies to protect individuals with diabetes and others NCDs in Brazil [31,32]. Although limited, if working well, this would at least protect them from encountering infected people seeking care. Meanwhile, at municipality level, certain locations successfully implemented alternative strategies, as hailed by one participant from an inland town: "my town adopted a delivery of medicine method for people with chronic diseases".

According to our data, especially individuals who exclusively depended on SUS were at higher risk, venturing out of home more often and experiencing an increase in blood glucose levels (Fig. 3). Differences would not be expected, since Brazil prides itself for its Universal Health Coverage, and most people, including the ones with private insurance, rely on SUS to receive part or all their medicines and supplies. We hypothesise that this finding highlights the socio-economic inequalities in the country, which exposes the less privileged more often to unsafe environments by forcing them to continue going out to work during the pandemic and/or to access affordable food.

Even though 44.3% of the individuals reported having a family member or friend going monthly to public pharmacies on their behalf to collect medicines and supplies, 49.9% went themselves, perhaps due to lack of direct support. It is important to highlight that family member's or friend's support may reduce but not eliminate the risk of infection, especially if residing in the same location, acting as a potential vehicle of indirect transmission. Another uncomfortable answer came from 5.8% of the individuals who reported halting

collection of their medicines and medical supplies and relying on personal stocks, which might not last the entire pandemic period. This situation may place those who avoided leaving their homes during the pandemic in a risky untreated situation, a globally shared concern [15,17,33,34,35].

While it is hard to predict social, economic and health impacts of a pandemic, specialists alert to the consequences of implementing only light measures [4,12,13,36,37,38], but, at the same time, also the harmful consequences of lockdowns, mobility restrictions and social distancing on the prevention and control of diabetes and other NCDs [17,34,39]. Barone et al. [39] reported an association between stricter measures against the pandemic and perceived challenges and fear in the diabetes community in South and Central America, which, when disconnected from information and educational strategies, would increase the pressure on the health systems [37,39].

Although decentralized (defined by states and municipalities) and delayed [1,4,12,13,40], the measures to contain the SARS-CoV-2 spread in Brazil, and reflected on mobility reduction, was experienced by 95.1% of this study's respondents in different degrees (with 26.9% never going outside their homes). Differently from Kluge et al.'s prediction [17], in our case it was not associated with increased consumption of alcohol, tobacco and unhealthy foods. Notwithstanding, physical activity was affected, being reduced for 59.5% of the respondents. Other researchers have also reported physical activity reductions during the pandemic, and alerted for the potential negative consequences on metabolic, cardiovascular and musculoskeletal health [41,42]. They alert that these effects are observed even after short periods of inactivity, are hard to recover and, not only increase premature mortality, but also favor the development of diabetes chronic complications [41,42]. A strategy to minimize those consequences would be developing good channels and partnerships for informing these populations through the internet, TV broadcasting and messaging through mobile phone applications in a structured manner, focusing on preventive measures and maintenance or improvement of habits and behaviors, such as regular physical activity [17,34,41,42,43]. This recommendation is compatible with the present findings where 87.4% of the individuals maintained or increased their time watching TV and 90.7% maintained or increased their time on the internet.

Regarding treatment, the COVID-19 pandemic, as predicted and observed by different authors, is impacting availability and access to healthcare professionals (HCPs) for the routine care of people with diabetes, since many of them relocated to emergency rooms, testing sites, ICUs and other services to attend infected individuals [15,17,33,34,39]. We found that 38.4% postponed their medical appointments and/or examinations. We attributed these results to shortage of HCPs, as expressed by 3 individuals in the comments space of the survey, reporting appointment cancelation or absence of physician; or personal decision because of the fear of getting infected at a hospital or clinic, as identified in other studies [39,35]. The potential consequence of this phenomenon of fear during the pandemic was reported in a pediatric emergency department, in Italy, with reduction and delay in children's arrival, which included cases of severe diabetes ketoacidosis and hypoglycemia [35].

Although online consultation and other telemedicine strategies were not investigated profoundly in the present study, one of the respondents commented that he/she was having online medical appointments. Brazilian laws and regulations became more flexible allowing this type of approach during the COVID-19 pandemic [44]. In alignment with other authors and international organizations, we highly recommend it [15,33,36,45,46,47,48], reinforcing Primary Health-care's role during the pandemic through ensuring close and timely monitoring of people with diabetes and other NCDs [37,44,49].

The results show that all types of diabetes were close to additional risk factors for poor prognosis of individuals infected by SARS-CoV-2. While T2D and unknown diabetes type (Fig. 1) appear near other NCDs (especially cardiovascular and obesity) [18,24,47,50,51], T1D and other types (LADA, MODY and gestational grouped) presented close proximity to glycemic variability (Fig. 2) [5,15,52]. Therefore, we suggest that none of the types should feel safe. Although, not surprising, T2D was associated with the category "50 years and older" (Fig. 1), reason to be vigilant, since the COVID-19 mortality and severity increase with age [5,24,53]. An unfortunate result was the proximity of individuals reporting increased blood glucose levels and the presence of COVID-19 symptoms without testing (Fig. 1). The global shortage of tests for SARS-CoV-2 poses a grand challenge [2–4], however, cognizant that high blood glucose increases the risk for infection severity and death [15,19,20,21,22,23], early testing efforts must be prioritized in this group. In addition, supporting the intensification of diabetes self-care practices to quickly bring individuals' glycemia back on track must be prioritized [45,51,54]. Fig. 2 depicts the importance of balancing food and exercise, since individuals who increased or decreased any of them experienced changes in their blood glucose levels, whereas those able to maintain exercise and food consumption avoided glycemic changes.

While the present study focused only on diabetes, WHO's data show that other NCDs serviced in similar health systems and pandemic environment are facing comparable challenges [55]. In terms of unattended needs of individuals with diabetes during this COVID-19 crisis, Brazil is not the only country with unaddressed demands. In a collection of testimonials from people with diabetes in different countries, the International Diabetes Federation exposed some similar issues whilst others different from the Brazilian context [56]. While the absence of specific measures to protect those with diabetes was reported in Greece and Spain, access to medicines was a challenge in Zimbabwe, Iran and India [56]. However, countries like Argentina, Italy, Portugal, and South Korea seemed to have adopted measures that made people with diabetes feel safer [48,56]. It is urgent for Brazil to follow international best practices and recommendations, since, as stated by the WHO Regional Office for Europe, "the prevention and control of NCDs have a crucial role in the COVID-19 response and an adaptive response is required to account for the needs of people with NCDs" [17].

The limitations of the present study include the fact that, although efforts were made to disseminate the survey as much as possible, its sample neither reflects the proportion of Brazilian population nor its fraction with diabetes. Thus, it is a convenience sample, without post-stratification

weights. Questions about behaviors, habits and glycemic changes were subjective comparisons with the pre-pandemic state, therefore, we did not have access to objective data to validate the subjective responses. As an online survey, it is biased by individuals who have internet access. While 17% of the Brazilian population have a college degree [57] and 27.9% have private health insurance [28], among the respondents of the present survey, 51.8% had at least one college degree and only 28.2% exclusively access care services through SUS.

Other demographic limitations are related to the age groups distribution, younger than the general population with the great majority of the respondents from Sao Paulo state, which would be about 20% of the country, not 42.6% as in our group of respondents. We understand that one of the main factors leading to this bias is the network in which the authors are engaged, the geographic location of diabetes associations and the profile of their active members; tendency to have more individuals with T1D than T2D, mostly young and highly educated. An additional limitation is the number of choices for each question and the aggregation made for analysis purposes. This includes the fact that if separated, diseases aggregated in the Cardiovascular Disease group, for example, could behave differently in terms of proximity to other factors. Moreover, increase or decrease of the blood glucose, interpreted as distancing from the target, would in fact have led the glycemia to target, while the ones who successfully maintained the blood glucose in pre-pandemic levels, may have kept it out of target.

5. Conclusion

As revealed for the first time in the current study, individuals with diabetes were not spared by the COVID-19 pandemic in Brazil. Measures and adjustments lacked or were insufficient, paving the way to unhealthy and unsafe behaviors such as postponing medical appointments, reducing physical activity and refraining from collecting medicines and supplies, which led to a high percentage of glycemic worsen reports. Additionally, announced measures for prevention and mitigation of COVID-19 consequences on this population, such as supply of medicines for 3 months, worked just for a minority.

In conclusion, we see a pressing need from the Brazilian federal, states and municipal authorities to broaden the implemented measures in order to reach more people, and partner with civil society, private sector and media channels to quickly improve the response and, this way, prevent a surge of individuals with diabetes infected by SARS-CoV-2 and of acute and chronic diabetes complications. Measures to keep individuals healthy, ensuring their glycemia is on target and allowing them to stay at home as much as possible must be prioritized. We recommend that the public and the private health systems maintain, adapt and strengthen programs for the continuity of care of individuals with diabetes and other NCDs, and develop information and educational campaigns on how to access these programs. In addition to focusing on reducing the risk of infection and continuity of their healthcare, these measures should facilitate access to healthcare professionals' counseling for therapeutic adjustment.

Finally, as key measures we foresee are a) active monitoring, informing, educating and responding to communities' needs at primary healthcare level; b) high quality telehealth for consultations, monitoring and examining; c) distribution of medications and supplies for three or more months, ideally with home delivery; and d) home sampling for scheduled lab exams, using mobile point-of-care strategies or appointment in specific facilities with well established disinfection protocols. Consequently, we believe that the pandemic's challenges can be lessened if appropriate measures protecting individuals with diabetes and other chronic conditions are adopted, and investments are not solely directed to purchasing mechanical ventilators and equipping tertiary care.

Acknowledgements

The authors acknowledge Vanessa Piroló's support and assistance sharing the survey through her network and the non-governmental organizations ADJ Diabetes Brasil (ADJ), Institute for Children with Diabetes (ICD), Brazilian Diabetes Society (SBD), Brazilian Hypercholesterolemia Association (AHF), FórumDCNTs and their member and partner entities for assisting in sharing the survey and providing general support.

Formatting of funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES

- [1] Rafael R, Neto M, Carvalho M, et al. Epidemiology, public policies and Covid-19 pandemics in Brazil: what can we expect?. *Revista de Enfermagem Uerj* 2020;28.
- [2] Croda J, Oliveira W, Frutuoso R, et al. COVID-19 in Brazil: advantages of a socialized unified health system and preparation to contain cases. *Sociedade Brasileira de Medicina Tropical*. 2020;53. <https://doi.org/10.1590/0037-8682-0167-2020>.
- [3] Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, Méndez CA, Zambrano LI, Franco-Paredes C, Suárez JA, Rodriguez-Enciso HD, Balbin-Ramon GJ, Savio-Larriera E, Risquez A, Cimerman S. COVID-19 in Latin America: the implications of the first confirmed case in Brazil. *Travel Med Infect Dis* 2020;35:101613. <https://doi.org/10.1016/j.tmaid.2020.101613>.
- [4] Kirby T. South America prepares for the impact of COVID-19. *Lancet* 2020. [https://doi.org/10.1016/S2213-2600\(20\)30218-6](https://doi.org/10.1016/S2213-2600(20)30218-6).
- [5] Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. *JAMA Network* 2020;323(13):1239–42. <https://doi.org/10.1001/jama.2020.2648>.
- [6] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet* 2020. [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5).
- [7] Rodriguez-Morales AJ, Sánchez-Duque JA, Hernández Botero S et al. Preparación y control de la enfermedad por coronavirus 2019 (COVID-19) en América Latina. *Acta Med Peru* 2020;37(1):3 <https://doi.org/10.35663/amp.2020.371.909>.
- [8] Bedford J, Enria D, Heymann D, et al. COVID-19: towards controlling of a pandemic. *Lancet* 2020;395(10229):P1015–8.
- [9] Lazzerini M, Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. *Lancet* 2020;8(5):E641–2. [https://doi.org/10.1016/S2214-109X\(20\)30110-8](https://doi.org/10.1016/S2214-109X(20)30110-8).
- [10] WHO. Coronavirus Disease (COVID-19) Pandemic, https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj0KCQjwhtT1BRciARisAGLY51IENPlv2UGpmxXy8AuUGkFbDKbMq5inFN5BVMjuo2O6n34GouGgdwAaAvEZEALw_wcB; 2020 [accessed 6 July 2020].
- [11] Coronavírus Brasil. Painel Coronavírus, <https://covid.saude.gov.br/>; 2020 [accessed 6 July 2020].
- [12] Lancet T. COVID-19 in Brazil: "So what?". *Lancet* 2020;395:1461. [https://doi.org/10.1016/S0140-6736\(20\)31095-3](https://doi.org/10.1016/S0140-6736(20)31095-3).
- [13] Mellan T, Hoeltgebaum H, Mishra S, et al. Report 21: Estimating COVID-19 cases and reproduction number in Brazil. Imperial College London. 2020; <https://doi.org/10.25561/78872>.
- [14] Ziegler MF. Pesquisadores estimam haver mais de 1,6 milhão de casos de COVID-19 no Brasil. Agência Fapesp. 2020; <http://agencia.fapesp.br/pesquisadores-estimam-haver-mais-de-16-milhao-de-casos-de-covid-19-no-brasil/33116/> [accessed 17 May 2020].
- [15] Gentile S, Strollo F, Ceriello A. Ceriello, COVID-19 Infection in Italian people with diabetes: lessons learned for our future (an experience to be used). *Diabetes Res Clin Pract* 2020;162:108137. <https://doi.org/10.1016/j.diabres.2020.108137>.
- [16] Wang W, Lu J, Gu W, Zhang Y, Liu J, Ning G. Care for diabetes with COVID-19: advice from China. *J Diabetes* 2020;12(5):417–9. <https://doi.org/10.1111/jdb.v12.5.10.1111/1753-0407.13036>.
- [17] Kluge H, Wickramasinghe K, Rippin H, et al. Prevention and control of non-communicable diseases in the COVID-19 response. *Lancet* 2020. [https://doi.org/10.1016/S0140-6736\(20\)31067-9](https://doi.org/10.1016/S0140-6736(20)31067-9).
- [18] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
- [19] Zhu L, She Z, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. *Cell Metab* 2020. <https://doi.org/10.1016/j.cmet.2020.04.021>.
- [20] Iacobellis G, Penaherrera CA, Bermudez LE, et al. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes. *Diabetes Res Clin Pract* 2020;164:108185. <https://doi.org/10.1016/j.diabres.2020.108185>.
- [21] Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. *J Diabetes Sci Technol* 2020:1–9. <https://doi.org/10.1177/1932296820924469>.
- [22] Codo AC, Davanzo GG, Monteiro LB. Elevated glucose levels favor Sars-Cov-2 infection and monocyte response through a Hif-1 α /glycolysis dependent axis. *Cell Metab* 2020. <https://doi.org/10.2139/ssrn.3606770>.
- [23] Ceriello A. Hyperglycemia and the worse prognosis of COVID-19. why a fast blood glucose control should be mandatory. *Diabetes Res Clin Pract* 2020;163:108186. <https://doi.org/10.1016/j.diabres.2020.108186>.
- [24] Shi Q, Zhang X, Jiang F, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center retrospective study. *Diabetes Care* 2020;43(5):1–10. <https://doi.org/10.2337/dc20-0598>.
- [25] International Diabetes Federation (IDF). *IDF Diabetes Atlas*. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.

- [26] Malta DC, Duncan BB, Schmidt MI et al. Prevalence of diabetes mellitus as determined by glycated hemoglobin in the Brazilian adult population, National Health Survey. *Rev. Bras. Epidemiol.* 2019;22(S2). <https://doi.org/10.1590/1980-549720190006.supl.2>.
- [27] Tenenhaus M, Young F. An analysis and synthesis of multiple correspondence analysis, optimal scaling, dual scaling, homogeneity analysis and other methods for quantifying categorical multivariate data. *Psychometrika* 1985;50:91–119. <https://doi.org/10.1007/BF02294151>.
- [28] Malta D, Stopa S, Pereira C, et al. Private health care coverage in the Brazilian population, according to the 2013 Brazilian National Health Survey. *Ciência & Saúde Coletiva* 2017;22(1):179–90. <https://doi.org/10.1590/1413-81232017221.16782015>.
- [29] PAHO. If I have diabetes, what do I need to know about COVID-19?. https://iris.paho.org/bitstream/handle/10665.2/52213/PAHONMHNVCVID-19200014_eng.pdf?sequence=5&isAllowed=y; 2020 [accessed 10 June 2020].
- [30] Bachiredy C, Chen C, Dar M. Securing the safety net and protecting health during a pandemic: medicaid's response to COVID-19. *JAMA* 2020;323(20):2009–10. <https://doi.org/10.1001/jama.2020.4272>.
- [31] Ministério da Saude. Alterações no Programa Farmácia Popular devido à situação de emergência de saúde pública decorrente do coronavírus (COVID19), <https://www.saude.gov.br/noticias/farmacia-popular/46566>; 2020 [accessed 10 June 2020].
- [32] Governo do Estado de Sao Paulo. Saúde amplia entrega de remédios nas farmácias de alto custo para prevenção do coronavírus, <http://www.portaldenoticias.saude.sp.gov.br/saude-amplia-entrega-de-remedios-nas-farmacias-de-alto-custo-para-prevencao-do-coronavirus/>; 2020 [accessed 10 June 2020].
- [33] Ma RCW, Holt RIG. COVID-19 and diabetes. *Diabet Med* 2020;37:723–5. <https://doi.org/10.1111/dme.14300>.
- [34] Katulanda P, Dissanayake H, Ranathunga I. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. *Diabetologia* 2020. <https://doi.org/10.1007/s00125-020-05164-x>.
- [35] Lazzarini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. *Lancet Child Adolesc Health* 2020;4(5):e10–1. [https://doi.org/10.1016/S2352-4642\(20\)30108-5](https://doi.org/10.1016/S2352-4642(20)30108-5).
- [36] Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. *Endocrine* 2020;68:2–5. <https://doi.org/10.1007/s12020-020-02294-5>.
- [37] Sánchez-Duque JA, Arce-Villalobos LR, Rodríguez-Morales AJ. Enfermedad por coronavirus 2019 (COVID-19) en América Latina: papel de la atención primaria en la preparación y respuesta. *Aten Primaria* 2020. <https://doi.org/10.1016/j.aprim.2020.04.001>.
- [38] Inglesby TV. Public health measures and the reproduction number of SARS-CoV-2. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.7878>.
- [39] Barone M, Villarroel D, de Luca P, et al. COVID-19 Impact on People with Diabetes in the South and Central America. *Diabetes Res Clin Pract* 2020;166:108301. <https://doi.org/10.1016/j.diabres.2020.108301>.
- [40] Cimerman S, Chebabo A, da Cunha CA, et al. Deep impact of COVID-19 in the healthcare of Latin America: the case of Brazil. *Braz J Infect Dis* 2020. <https://doi.org/10.1016/j.bjid.2020.04.005>.
- [41] Peçanha T, Goessler KF, Roschel H, et al. Social isolation during the COVID-19 pandemic can increase physical inactivity and the global burden of cardiovascular disease. *Am J Physiol Heart Circ Physiol* 2020;318(6):H1441–6. <https://doi.org/10.1152/ajpheart.00268.2020>.
- [42] Roschel H, Artioli GG, Gualano B. Risk of increased physical inactivity during COVID-19 outbreak in older people: a call for actions. *J Am Geriatr Soc* 2020. <https://doi.org/10.1111/jgs.16550>.
- [43] Hopman J, Allegranzi B, Mehtar S. Managing COVID-19 in low- and middle-income countries. *JAMA* 2020;323(16):1549–50. <https://doi.org/10.1001/jama.2020.4169>.
- [44] Sarti T, Lazarini W, Fontenelle L, et al. What is the role of primary health care in the COVID-19 pandemic?. *Epidemiol Serv Saude* 2020;29(2). <https://doi.org/10.5123/S1679-49742020000200024>.
- [45] Bornstein S, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. *Lancet* 2020. [https://doi.org/10.1016/S2213-8587\(20\)30152-2](https://doi.org/10.1016/S2213-8587(20)30152-2).
- [46] Peters A, Garg S. The silver lining to COVID-19: avoiding diabetic ketoacidosis admissions with telehealth. *Diabetes Technol Ther* 2020;22(6):1–5. Available from: <https://www.liebertpub.com/doi/pdfplus/10.1089/dia.2020.0187>.
- [47] Drucker D. Coronavirus infections and type 2 diabetes - shared pathways with therapeutic implications. *Endocr Rev* 2020;41(3):1–13. <https://doi.org/10.1210/endo/bnaa011>.
- [48] World Health Organization, Regional Office for Europe. Ensuring people-centred diabetes care during the COVID-19 pandemic Experiences from Portugal (2020), http://www.euro.who.int/__data/assets/pdf_file/0011/444791/Diabetes-care-during-COVID-19-eng.pdf?ua=1; 2020 [accessed 10 June 2020].
- [49] Beran D, Perone SA, Perolini MC, et al. Beyond the virus: Ensuring continuity of care for people with diabetes during COVID-19. *Primary Care Diabetes* 2020. <https://doi.org/10.1016/j.pcd.2020.05.014>.
- [50] Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. *Diabetes Care* 2020. <https://doi.org/10.2337/dc20-0576>.
- [51] Hussain A, Bhowmik B, Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. *Diabetes Res Clin Pract* 2020;162:108142. <https://doi.org/10.1016/j.diabres.2020.108142>.
- [52] Ebekozien OA, Noor N, Gallagher MP et al. Type 1 Diabetes and COVID-19: preliminary findings from a multicenter surveillance study in the U.S. *Diabetes Care*. 2020;dc201088. doi: 10.2337/dc20-1088.
- [53] Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy. *JAMA Network* 2020;323(16):1545–6. <https://doi.org/10.1001/jama.2020.4031>.
- [54] Gupta R, Ghosh A, Singh AK, et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. *Diabetes Metabolic Syndrome: Clin Res Rev* 2020;14(3):211–2. <https://doi.org/10.1016/j.dsx.2020.03.002>.
- [55] World Health Organization, Rapid assessment of service delivery for NCDs during the COVID-19 pandemic, [https://www.who.int/docs/default-source/ncds/ncd-covid-19/for-web-rapid-assessment-29-may-2020-\(cleared\).pdf?sfvrsn=6296324c_8&download=true](https://www.who.int/docs/default-source/ncds/ncd-covid-19/for-web-rapid-assessment-29-may-2020-(cleared).pdf?sfvrsn=6296324c_8&download=true); 2020 [accessed 10 June 2020].
- [56] International Diabetes Federation. COVID-19: Perspectives from people with diabetes. *Diabetes Res Clin Pract*. 2020 May;163:108201. doi: 10.1016/j.diabres.2020.108201.
- [57] OECD. Education at a Glance 2019. Country Note Brazil; https://www.oecd.org/education/education-at-a-glance/EAG2019_CN_BRA.pdf; 2019 [accessed 10 June 2020].